AI assistant
OptimizeRx Corp — Director's Dealing 2021
Oct 13, 2021
33090_dirs_2021-10-13_dc363dc4-6c69-4b29-b109-753e28e6f5fb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2021-10-11
Reporting Person: Stelmakh Edward (COO and CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-11 | Restricted Stock Units | $ | A | 24664 | Acquired | Common Stock (24664) | Direct | |
| 2021-10-11 | Stock Option | $81.09 | A | 25191 | Acquired | 2026-10-11 | Common Stock (25191) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted will vest 1/3 at the end of each anniversary from issuance, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction.
F3: Not applicable.
F4: The Stock Option will vest 1/3 at the end of each anniversary from issuance.